A specific monoclonal antibody 131I-labeled CD147 has been developed and utilized combined with radiofrequency ablation or TACE for HCC treatment, suggesting its potential use as a targeted therapy for HCC [118]. This evidence concerns the gene BSG and hepatocellular carcinoma.